Stem cells may supercharge CAR t for tough blood cancers
NCT ID NCT05887167
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 days after CAR T infusion. The main goals are to see if enough stem cells can be collected and to monitor side effects like cytokine release syndrome and nerve toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous hematopoietic stem cells (aHSCs) combined with FDA-approved CAR T-cell therapy
- What this could lead to
- If successful, this approach could make CAR T therapy safer and more effective for patients with hard-to-treat blood cancers.
- What could go wrong
- This is a very early phase 1 trial with only 20 participants, so results may not apply broadly. Adding stem cells could also increase risks like graft-versus-host disease or other complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?